Who are Tegretol's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Carbamazepin, Lithobid, CARBAMAZEPINE, lamotrigine (generic Teva), Lithium / Fluoxetine, lamotrigine (brand Lamictal).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/carbamazepine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Tegretol — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Tegretol (carbamazepine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Mood Stabilizer [EPC]. Area: Neuroscience.

marketed Mood Stabilizer [EPC] Frizzled-8, Nuclear receptor subfamily 1 group I member 2, Neuronal acetylcholine receptor; alpha2/beta4 Neuroscience Small molecule Live · refreshed every 30 min

Target snapshot

Tegretol (carbamazepine) — Novartis AG (originally Geigy). Carbamazepine reduces polysynaptic responses and blocks post-tetanic potentiation, potentially alleviating seizures and pain.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Tegretol TARGET	carbamazepine	Novartis AG (originally Geigy)	marketed	Mood Stabilizer [EPC]	Frizzled-8, Nuclear receptor subfamily 1 group I member 2, Neuronal acetylcholine receptor; alpha2/beta4	1968-03-11
Carbamazepin	Carbamazepin	Enanta Pharmaceuticals, Inc	marketed		Frizzled-8, Nuclear receptor subfamily 1 group I member 2, Neuronal acetylcholine receptor; alpha2/beta4
Lithobid	lithium carbonate	Generic (multiple manufacturers)	marketed	Mood stabilizer	Inositol-1(or 4)-monophosphatase 1, Glycogen synthase kinase-3	1970-04-06
CARBAMAZEPINE	CARBAMAZEPINE		marketed	Mood Stabilizer [EPC]		1968-01-01
lamotrigine (generic Teva)	lamotrigine (generic Teva)	University of Maryland, Baltimore	marketed	Anticonvulsant / Mood stabilizer	Voltage-gated sodium channels; glutamate release inhibition
Lithium / Fluoxetine	Lithium / Fluoxetine	University of Pennsylvania	marketed	SSRI + mood stabilizer combination	Serotonin transporter (SERT); inositol monophosphatase
lamotrigine (brand Lamictal)	lamotrigine (brand Lamictal)	University of Maryland, Baltimore	marketed	Anticonvulsant / Mood stabilizer	Voltage-gated sodium channels; glutamate release inhibition

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2028-11-10 — Tegretol · 9770407 · Formulation · US
2028-11-10 — Tegretol · 9629797 · Method of Use · US
2029-03-13 — Tegretol · 9750822 · Formulation · US
2029-03-13 — Tegretol · 7635773 · Formulation · US
2029-03-13 — Tegretol · 8410077 · Formulation · US
2033-02-27 — Tegretol · 9493582 · Formulation · US
2040-01-31 — Tegretol · 11529357 · Formulation · US

Sponsor landscape (Mood Stabilizer [EPC] class)

· 1 drug in this class
Novartis AG (originally Geigy) · 1 drug in this class
Pfizer Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Tegretol — Competitive Intelligence Brief. https://druglandscape.com/ci/carbamazepine. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing